Hemolysis Overview
Learn About Hemolysis
Red blood cells normally live for 110 to 120 days. After that, they naturally break down and are most often removed from the circulation by the spleen.
Some diseases and processes cause red blood cells to break down too soon. This requires the bone marrow to make more red blood cells than normal. The balance between red blood cell breakdown and production determines how low the red blood cell count becomes. If the red blood cell count becomes abnormally low, it is called hemolytic anemia.
Conditions that can cause hemolysis include:
- Immune reactions
- Infections
- Medicines
- Toxins and poisons
- Red blood cell metabolism or defects in the shape of blood cells
Hemolysis is the breakdown of red blood cells.
Austin Kulasekararaj practices in London, United Kingdom. Kulasekararaj and is rated as an Elite expert by MediFind in the treatment of Hemolysis. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Hemolysis, Anemia, and Bone Marrow Transplant.
Jun-ichi Nishimura practices in Osaka, Japan. Nishimura and is rated as an Elite expert by MediFind in the treatment of Hemolysis. His top areas of expertise are Paroxysmal Cold Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria (PNH), Hemolysis, and Hemolytic Anemia.
Johns Hopkins University
Robert Brodsky is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Brodsky and is rated as an Elite provider by MediFind in the treatment of Hemolysis. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is currently accepting new patients.
Summary: the restless leg syndrome is a common complaint in person who undergo hemodialysis. Buddhist walking meditation efficacy was not investigated in those population
Summary: Autoimmune hemolytic anemia (AIHA) is a rare autoimmune disease (incidence \<1/100,000 population) responsible for the destruction of red blood cells by the host immune system, notably through the action of autoantibodies. Apart from complications related to anemia, the occurrence of venous thromboembolism (VTE) in this population is frequent, estimated at 20-27%. The risk of VTE is highest during...
Published Date: March 31, 2024
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Elghetany MT, Banki K. Erythrocytic disorders. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Philadelphia, PA: Elsevier; 2022:chap 33.
Gallagher PG. Red blood cell membrane disorders. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 46.
Gallagher PG. Hemolytic anemias: red blood cell membrane and metabolic defects. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 147.
Gregg XT, Prchal JT. Red blood cell enzymopathies. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 45.
Mentzer WC, Schrier SL. Extrinsic nonimmune hemolytic anemias. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 48.
Michel M. Autoimmune and intravascular hemolytic anemias. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 146.